136 related articles for article (PubMed ID: 30902657)
21. Relevance of FXR-p62/SQSTM1 pathway for survival and protection of mouse hepatocytes and liver, especially with steatosis.
Haga S; Yimin ; Ozaki M
BMC Gastroenterol; 2017 Jan; 17(1):9. PubMed ID: 28086800
[TBL] [Abstract][Full Text] [Related]
22. A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys.
Chiang PC; Thompson DC; Ghosh S; Heitmeier MR
J Pharm Sci; 2011 Nov; 100(11):4722-33. PubMed ID: 21660973
[TBL] [Abstract][Full Text] [Related]
23. Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model.
Gao R; Gao W; Xu G; Xu J; Ren H
World J Gastroenterol; 2017 Jul; 23(28):5158-5166. PubMed ID: 28811710
[TBL] [Abstract][Full Text] [Related]
24. Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
Westhaus S; Deest M; Nguyen ATX; Stanke F; Heckl D; Costa R; Schambach A; Manns MP; Berg T; Vondran FWR; Sarrazin C; Ciesek S; von Hahn T
J Hepatol; 2017 Aug; 67(2):237-245. PubMed ID: 28363797
[TBL] [Abstract][Full Text] [Related]
25. Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice.
Liu X; Guo GL; Kong B; Hilburn DB; Hubchak SC; Park S; LeCuyer B; Hsieh A; Wang L; Fang D; Green RM
Hepatology; 2018 Jul; 68(1):304-316. PubMed ID: 29377207
[TBL] [Abstract][Full Text] [Related]
26. Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice.
Liu HM; Liao JF; Lee TY
Biochem Biophys Res Commun; 2017 Aug; 490(3):841-848. PubMed ID: 28647362
[TBL] [Abstract][Full Text] [Related]
27. A rapid administration of GW4064 inhibits the NLRP3 inflammasome activation independent of farnesoid X receptor agonism.
Xie S; Guo C; Chi Z; Huang B; Wu Y; Wang D; Xia D
FEBS Lett; 2017 Sep; 591(18):2836-2847. PubMed ID: 28787755
[TBL] [Abstract][Full Text] [Related]
28. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation.
Hu T; Chouinard M; Cox AL; Sipes P; Marcelo M; Ficorilli J; Li S; Gao H; Ryan TP; Michael MD; Michael LF
J Biol Chem; 2006 Dec; 281(52):39831-8. PubMed ID: 17065154
[TBL] [Abstract][Full Text] [Related]
29. Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.
Gege C; Kinzel O; Steeneck C; Schulz A; Kremoser C
Curr Top Med Chem; 2014; 14(19):2143-58. PubMed ID: 25388536
[TBL] [Abstract][Full Text] [Related]
30. [Effects of farnesoid X receptor agonist on adiponectin and its receptors].
Xin X; Zhong M; Zhang S; Peng Y; Zhu W; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jan; 34(1):109-12. PubMed ID: 24463129
[TBL] [Abstract][Full Text] [Related]
31. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
32. FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake.
Li L; Zhao H; Chen B; Fan Z; Li N; Yue J; Ye Q
J Transl Med; 2019 Dec; 17(1):418. PubMed ID: 31836014
[TBL] [Abstract][Full Text] [Related]
33. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
[TBL] [Abstract][Full Text] [Related]
34. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins.
Li X; Li J; Feng Y; Cai H; Li YP; Peng T
Antiviral Res; 2020 May; 177():104734. PubMed ID: 32057770
[TBL] [Abstract][Full Text] [Related]
35. Activation of the farnesoid X receptor attenuates triptolide-induced liver toxicity.
Jin J; Sun X; Zhao Z; Wang W; Qiu Y; Fu X; Huang M; Huang Z
Phytomedicine; 2015 Sep; 22(10):894-901. PubMed ID: 26321738
[TBL] [Abstract][Full Text] [Related]
36. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
[TBL] [Abstract][Full Text] [Related]
37. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
38. Regulation of carbohydrate metabolism by the farnesoid X receptor.
Stayrook KR; Bramlett KS; Savkur RS; Ficorilli J; Cook T; Christe ME; Michael LF; Burris TP
Endocrinology; 2005 Mar; 146(3):984-91. PubMed ID: 15564327
[TBL] [Abstract][Full Text] [Related]
39. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
[TBL] [Abstract][Full Text] [Related]
40. Entry of pseudotyped hepatitis C virus into primary human hepatocytes depends on the scavenger class B type I receptor.
Régeard M; Trotard M; Lepère C; Gripon P; Le Seyec J
J Viral Hepat; 2008 Dec; 15(12):865-70. PubMed ID: 19087225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
